Background {#Sec1}
==========

Duchenne Muscular Dystrophy (DMD) is a progressive and fatal X-linked \[[@CR1]\] neuromuscular disorder afflicting 1 in 3500--5000 live male births \[[@CR2]\]. DMD arises from the loss of dystrophin \[[@CR3]\], a 427 kDa cytoskeletal protein \[[@CR4]\] that links the contractile apparatus to the sarcolemma via the dystrophin-associated protein complex (DPC). Dystrophin is believed to provide stability and integrity to the muscle membrane during contraction and in its absence, skeletal muscle is prone to damage. The alterations to the membrane induced by dystrophin-deficiency leads to an excessive influx of calcium (Ca^2+^) from the extracellular environment, which is poorly buffered, and activates Ca^2+^-dependent proteases to induce a cascade of degeneration and damage. As the disease progresses, and damage and degeneration accrues, the regenerative capacity of the muscle diminishes and becomes unable to match the demand for repair \[[@CR5]\]. Muscle is subsequently replaced with fibrous and/or fatty connective tissue. Clinically, the increasing presence of non-functional muscle leads to muscle weakness and loss of function, with DMD sufferers wheelchair bound by early adolescence and eventually succumbing to cardiorespiratory failure by the third decade of life \[[@CR6]\].

It is most commonly accepted that the excessive influx of Ca^2+^ into dystrophin-deficient myofibres is the catalyst for dystrophinopathy. However, emerging evidence suggests that metabolic and mitochondrial dysfunction may play a significant role in disease progression \[[@CR7]--[@CR9]\]. Whether this dysfunction is a secondary consequence to dystrophin-deficiency or independent is unknown, however a physical link between dystrophin and metabolism exists in neuronal nitric oxide synthase (nNOS). nNOS is an enzyme usually localised to the sarcolemma attached to the DPC, however in the absence of dystrophin, there is a secondary reduction of nNOS \[[@CR10], [@CR11]\]. The loss of nNOS from the sarcolemma reduces overall nNOS content in dystrophic muscle \[[@CR12]--[@CR15]\] resulting in decreased nNOS activity \[[@CR12]--[@CR15]\] and NO production \[[@CR16]--[@CR18]\]. The loss of nNOS protein and subsequently NO production capacity and bioavailability, is detrimental to dystrophic muscle for two reasons. Firstly, NO is an important signalling molecule involved in many biological processes including metabolism, blood flow and regulation of muscle function and mass \[[@CR19]\]. Secondly, the nNOS protein itself interacts with phosphofructokinase (PFK), a regulatory enzyme of glycolysis, and is capable of increasing its activity by 60-fold \[[@CR20]\] thereby increasing glycolytic rate and capacity. The loss of association between nNOS and PFK in dystrophin-deficient muscle may help to explain the fatigability of dystrophic muscle \[[@CR21], [@CR22]\] and may partially or fully account for the various glycolytic impairments observed \[[@CR20], [@CR23], [@CR24]\]. In addition to the vast deficits in mitochondrial function (for detailed reviewed see \[[@CR9]\]), these metabolic impairments reduce energy production capacity \[[@CR7]\] and resting energy content \[[@CR25], [@CR26]\] which severely limits the muscles capacity to buffer damage and facilitate repair. As it appears that NO plays an important role in metabolism and the maintenance of skeletal muscle mass, restoring NO bioavailability in dystrophin-deficient muscle may be beneficial (summarised in Table [1](#Tab1){ref-type="table"}). Here, we review the various approaches to restore NO bioavailability in dystrophic muscle including nNOS overexpression, ˪-arginine administration, phosphodiesterase (PDE) inhibition and nitrate supplementation, with a focus on the effects on the architecture, function and metabolism of dystrophin-deficient skeletal muscle.Table 1Summary of methods utilised to increase NO production and the effects observed in dystrophic skeletal and cardiac muscle from DMD animal models and patientsMethod/MechanismDosage RangeModelEffectsOtherReferencenNOS restoration\
*Breeding with transgenic nNOS overexpressors*\
*Transfection with nNOS*N/A*mdx* mouse\
Dystrophin/utrophin knockout mouse\
*mdx* mouse*Skeletal muscle:* reduces inflammation, macrophage and neutrophil infiltration, damage\
*Cardiac muscle:* reduces fibrosis, macrophage infiltration, improves impulse conduction\
*Skeletal muscle:* increases DPC expression, NO production, reduces damage and fatigue, prevents force production loss\[[@CR39]--[@CR45], [@CR47]--[@CR49]\]˪-arginine supplementation200--1000 mg/kg/dayDMD patients\
*mdx* mouse*Skeletal muscle:* increases DPC expression, reduces damage, fibrotic and fatty tissue infiltration, inflammatory cell infiltration, oxidative stress, improves grip strength, contractile function and reduces fatigabilityAdministered in combination with metformin and prednisone\[[@CR18], [@CR29]--[@CR36]\]PDE inhibition\
*Sildenafil*\
*Tadalafil*0.7--80 mg/kg/day\
30--300 mg/kg/dayDMD patients\
*mdx* mouse\
DMD patients\
*mdx* mouse*Skeletal muscle:* reduces collagen and inflammatory cell infiltration, improves sarcolemmal integrity\
*Cardiac muscle:* reduces membrane permeability, induces cardiac remodelling, improves heart function\
*Skeletal muscle:* improves functional ischemia, reduces contraction-induced damage, fibrotic infiltration, histological variability, improves exercise performance, increases expression of ETC. genes\[[@CR52], [@CR55], [@CR57]--[@CR61]\]NO donation21--80 mg/kg/day*mdx* mouse*Skeletal muscle:* increases vascularisation, blood flow, exercise performance and strength, decreases free Ca^2+^ concentration, damage, inflammation, fibrotic and collagenous infiltration\
*Cardiac muscle:* decreases damage, inflammation, fibrotic and collagenous infiltration, improves cardiac function and architectureAdministered in combination with NSAIDs\[[@CR62]--[@CR69]\]Expansion of nitrate-nitrite-NO pool85 mg/L*mdx* mouse*Skeletal muscle:* does not improve mitochondrial deficits, increases damage and peroxynitrite productionOnly one study to date\[[@CR107]\]

Increasing nNOS substrate availability {#Sec2}
--------------------------------------

NO is an important signalling molecule that elicits a myriad of physiological effects through the production of cyclic guanosine monophosphate (cGMP) and/or S-nitrosylation of thiol residues of cysteine groups. cGMP is a second messenger produced by the binding of NO to the enzymatic receptor soluble guanylyl cyclase (sGC) \[[@CR27]\]. The increase in cytoplasmic cGMP activates downstream cGMP specific protein kinases, cation channels and PDEs which then exert various biological effects \[[@CR27]\]. NO also mediates its effects through S-nitrosylation, a post-translational modification of proteins that modulates enzyme activity, protein stability and localisation \[[@CR28]\]. Since the secondary dissociation of nNOS from the sarcolemma in dystrophic skeletal muscle reduces NO bioavailability, which would impair a multitude of physiological processes that may contribute to disease progression, various techniques to increase NO production have been investigated.

Considering that nNOS delocalisation from the sarcolemma does not completely obliterate the nNOS protein in dystrophic skeletal muscle \[[@CR11]\], substrate availability, in the form of ˪-arginine, may be a limiting factor to nNOS-dependent NO production (Fig. [1](#Fig1){ref-type="fig"}). ˪-arginine (50--100 mg/kg) administration in the *mdx* mouse demonstrably improves sarcolemmal integrity as indicated by increased utrophin -- a dystrophin analogue -- \[[@CR18], [@CR29]--[@CR33]\] and DPC protein expression \[[@CR18], [@CR30]--[@CR33]\], reduced Evans Blue Dye (EBD) uptake -- a marker of skeletal muscle membrane damage -- \[[@CR18], [@CR32]--[@CR34]\] and decreased serum creatine kinase levels -- a clinical marker of muscle damage and disease progression \[[@CR30], [@CR32], [@CR33]\]. In a pilot trial involving 5 DMD patients, the combination of ˪-arginine (7.5 g/day) and the pharmacological Adenosine Monophosphate-activated Protein Kinase (AMPK)-activator, metformin (500 mg/day), decreased resting energy expenditure, shifted energy metabolism substrate preference to fatty acids, reduced oxidative stress and improved motor function \[[@CR35]\]. NO is a known activator of AMPK, highlighting that promoting both the production of NO (i.e., with ~L~-arginine) and the downstream metabolic responses that are normally modulated by NO (i.e., with metformin) can functionally improve the metabolism and function of dystrophic skeletal muscle. In a subsequent single-centre, randomised, placebo controlled-trial, aimed at recruiting 40--50 DMD patients, the same group is currently investigating the efficacy of combined ʟ-citrulline and metformin (NCT01995032; \[[@CR36]\]) -- ʟ-citrulline was chosen for this trial it is an ʟ-arginine precursor that can demonstrably restore muscular ʟ-arginine levels and reduce muscle wasting in ʟ-arginine-deficient conditions, while having a self-mediated effect on protein metabolism via inducible (i)NOS which bypasses the obvious nNOS deficiency \[[@CR37]\]. ʟ-arginine therapy has also proven beneficial to skeletal muscle in the *mdx* mouse (a genetically homologous murine model of DMD). Histologically, ˪-arginine therapy improves many of the characteristic myopathological hallmarks in *mdx* mice including reductions in fatty and fibrotic tissue and collagen deposition \[[@CR30]--[@CR32], [@CR38]\], inflammatory cell infiltration \[[@CR31]\] and necrosis \[[@CR18], [@CR30], [@CR32]\]. Functional improvements in grip strength \[[@CR32], [@CR33]\], lesser decrement in strength with age \[[@CR38]\], and improved respiratory function \[[@CR30], [@CR32]\] were also observed. In addition to these functional improvements, ˪-arginine demonstrably reduces dystrophic muscle fatigability \[[@CR33]\] and improves contractile function \[[@CR30], [@CR32]\] resulting in an increased capacity to exercise \[[@CR34]\]. Whilst ˪-arginine administration appears to be beneficial both in the *mdx* mouse and DMD patients, the significantly reduced nNOS content evident in DMD patients suggests that there is a limited therapeutic application for ˪-arginine unless concomitant increases in nNOS expression could be achieved, or alternative isoforms of NOS could be exploited (i.e. through iNOS as per ʟ-citrulline therapy). This is especially true since ˪-arginine administration alone, especially in high doses, can have adverse side effects \[[@CR39]\]. Indeed, a recent paper describing metabolic biomarkers of DMD demonstrates significantly elevated serum arginine concentrations in DMD patients as the disease progresses \[[@CR40]\], highlighting the possibility of an ineffective uptake either alone or in combination with an ineffective metabolism due to reduced nNOS protein at the skeletal muscle level. While reduced ʟ-arginine transporter protein expression has been demonstrated in cardiac muscle from two murine models of DMD (*mdx* and *mdx*/*utrophin* double knockdown mice) \[[@CR41]\], there is no data describing this deficit in skeletal muscle either in mice or in human DMD patients. Such a deficit would logically explain a reduced capacity for ʟ-arginine uptake resulting in plasma accumulation, and may be a consequence of a reduced capacity for metabolism by nNOS.Fig. 1Schematic of methods utilised to increase NO bioavailability in dystrophic skeletal muscle and the downstream effects. Increasing NO bioavailability through (1) restoration of nNOS, (2) ˪-arginine supplementation, (3) NO donation and (4) inhibition of the enzyme phosphodiesterase (PDE) has led to increases in mitochondrial function, exercise capacity and stabilisation of the membrane in dystrophin-deficient skeletal muscle. A potential consequence of increased NO bioavailability, as observed through nitrate supplementation (5), is peroxynitrite (ONOO^−^) formation which can lead to further muscle damage and is undesirable in dystrophic skeletal muscle

Restoring nNOS protein expression {#Sec3}
---------------------------------

Given that the limiting factor to nNOS substrate supplementation therapy would be sufficient nNOS to catalyse the NO-generating reaction, restoring nNOS protein, particularly to the sarcolemma, presents as a strong therapeutic candidate. Indeed, restoring nNOS levels in dystrophic skeletal muscle has proven to be beneficial (Fig. [1](#Fig1){ref-type="fig"}). Offspring of transgenic nNOS overexpressors bred with the *mdx* mouse show a significant mitigation of membrane damage as reflected by a reduction in inflammation, macrophage and neutrophil infiltration, centronucleation of fibres and membrane lesions \[[@CR42], [@CR43]\]. Introduction of this nNOS transgene also extends protective effects to the dystrophic heart by reducing fibrosis and macrophage infiltration in conjunction with improving impulse conduction \[[@CR44]\]; and to the neuromuscular junction through improvements in neuromuscular junction size and architecture in the presence of α-syntrophin \[[@CR45]\]. Remarkably, nNOS restoration in *dystrophin/utrophin* knockout mice (which phenotypically resemble DMD) increases survival rate while reducing macrophage infiltration and the fibrotic and connective tissue content of dystrophin deficient skeletal muscle \[[@CR46]\]. Therefore, increased expression of nNOS has a protective effect on maintaining muscle architecture and preventing membrane lysis through the normalisation of NO production \[[@CR47]\]. Moreover, transfection with a modified muscle specific nNOSμ isoform -- which localises to the membrane without the presence of dystrophin -- resulted in increased expression of utrophin and other DPC proteins (including α-syntrophin and β-dystroglycan) which induced localised NO production at the sarcolemma and protection against contraction-induced damage and fatigue \[[@CR48]\]. In contrast, an unmodified nNOSμ afforded less protection than the modified muscle-specific nNOSμ isoform in the same study \[[@CR48]\]. This appears to be reflective of the binding of the modified NOS to the membrane via palmitoylation which induced utrophin expression. While the mechanism as to why membrane-localised nNOS induces utrophin expression is unclear. This utrophin upregulation seems to protect dystrophic *mdx* muscle from progressive damage, particularly as *mdx* mice age \[[@CR49]\], thus attenuating the dystrophic phenotype despite the absence of dystrophin expression. Insertion of a mini-dystrophin gene via a dual adeno-associated viral vector which increases mini-dystrophin expression and restores nNOS at the sarcolemma \[[@CR50]\], has also been shown to improve contraction-induced ischemia and mitigate the loss of force production and muscle damage \[[@CR51], [@CR52]\]. Collectively, these data highlight that increased expression of the nNOS protein, irrespective of localisation within the cell, can improve various characteristics of the dystrophic condition. However, there may be limited long-term therapeutic potential for nNOS overexpression as a delocalised nNOS (from the sarcolemmal DPC) becomes a substrate of calpains \[[@CR53]\]. Calpains are enzymes that stimulate protein damage and are particularly active in DMD pathology \[[@CR54]\]. Thus increased calpain activity may significantly reduce unbound nNOS expression and induce further non-specific protein damage. Since nNOS deficiency has also been documented to increase ryanodine receptor-mediated Ca^2+^ leak \[[@CR55]\], which would perpetuate Ca^2+^-dependent calpain activity, these data indicate that there is necessity in dual upregulation of nNOS and dystrophin to minimise unbound nNOS as a target for calpains which would promote the disease phenotype.

Inhibition of phosphodiesterase activity {#Sec4}
----------------------------------------

Given that enhancing NO production capacity is beneficial in dystrophic muscle yet there are complexities associated with re-insertion/establishment of dystrophin and nNOS expression, other mechanisms to increase NO bioavailability have been investigated. One such avenue is the inhibition of the PDE family which breakdown phosphodiester bonds in second messenger molecules \[[@CR56]\]. Specific PDEs hydrolyse cGMP thereby degrading it and decreasing cGMP second messenger capacity \[[@CR56]\]. Since NO activates cGMP cycling, and it's production and bioavailability is reduced in dystrophic muscle, pharmacologically prolonging/amplifying the cGMP signal would have likely benefits in NO-deficient cells (Fig. [1](#Fig1){ref-type="fig"}).

Inhibition of PDE5A has been commonly investigated in the *mdx* mouse as PDE5A is present not only in vascular smooth muscle \[[@CR57]\], but also skeletal muscle \[[@CR58]\] and to a lesser extent cardiac muscle \[[@CR59]\], thereby allowing for a systemic effect of a prolonged NO signal in these tissues. Treatment with Tadalafil (1 mg/100 mL), a pharmacological PDE5A inhibitor, has shown to be beneficial in overcoming functional ischaemia following contraction, which was partnered with reduced contraction-induced sarcolemmal damage and muscle fibre death \[[@CR60]\]. Tadalafil treated *mdx* muscles (30 mg/kg/day) also demonstrated histological improvements with a decrease in EBD uptake, fibrotic infiltration, centronucleated fibres and fibre size variability \[[@CR60], [@CR61]\] suggesting less damage and prevention of muscle degeneration. Additionally, exercise-induced damage was minimised in Tadalafil treated mice as evidenced by reduced Ca^2+^ accumulation \[[@CR61]\]. Functionally, time to exhaustion from treadmill running and extensor digitorum longus (EDL) strength were concomitantly improved following Tadalafil treatment \[[@CR61]\] in addition to post-exercise increases in activity and reductions in serum creatine kinase and muscle oedema \[[@CR62]\]. PGC-1α expression was also increased following Tadalafil treatment alongside an enhanced expression of various electron transport chain genes suggestive of a fibre type shift to an oxidative phenotype \[[@CR61]\]. Considering the vast mitochondrial and oxidative metabolism deficiencies observed in dystrophic muscle \[[@CR9]\], upregulation of mitochondrial and oxidative genes would likely be beneficial to dystrophic muscle. Only two studies to date have documented the successful translation of Tadalafil treatment into small populations of DMD \[[@CR63]\] and Becker Muscular Dystrophy (BMD) \[[@CR64]\] patients. Although these trials were small, and primarily assessed improvements in functional muscle ischaemia as an endpoint measure, these results demonstrate that the beneficial effects of PDE5A inhibitors in pre-clinical studies are translatable in patients with dystrophin-deficiency. In particular, both of these studies utilised an acute treatment protocol (up to 2 days) with endpoint measures assessed an hour following treatment indicating an effect of PDE5A inhibition in these populations. A recent study by Hammers et al. \[[@CR65]\] has also demonstrated a cardioprotective role for Tadalafil whereby a daily dosage of 1 mg/kg for 16 months reduced dystrophy-related histopathological features, calpain-mediated proteolysis and preserved cardiac function (as assessed by echocardiography and MRI). A notable limitation to this study was the low number of animals utilised (*n* = 2 DMD and control).

Similar results have been observed with the alternative PDE5A inhibitor, Sildenafil. In *mdx* mice, Sildenafil demonstrably increases specific force, reduces collagen I, fibronectin and TNFα infiltration, and improves sarcolemmal integrity of the diaphragm \[[@CR66]\]. However, these improvements did not result in changes to mitochondrial function nor improvements in ATP production as originally hypothesised \[[@CR67]\]. Since DMD patients typically succumb to respiratory failure, these data importantly highlight the potential for Sildenafil to prolong the lifespan of DMD patients should diaphragmatic improvements be translatable in the clinical setting. Following phenotypic drug screening in dystrophic zebrafish, a PDE inhibitor (aminophylline), which has similar properties to Sildenafil, was shown to have the greatest capacity to restore normal skeletal muscle structure \[[@CR68]\]. The group later demonstrated beneficial effects of Sildenafil in the *mdx* ^*5cv*^ mouse model via enhanced signalling of haemoxygenase and downstream cGMP \[[@CR69]\]. Sildenafil also appears to induce protective effects in the *mdx* heart by reducing membrane permeability and altering the expression of proteins implicated in beneficial cardiac remodelling \[[@CR70]\]. Functionally, Sildenafil normalises heart rate responses to increasing workload \[[@CR70]\] and reverses ventricular dysfunction \[[@CR71]\]. Again, since cardiac complications reduce lifespan in DMD patients, these data appear to be promising should they be translatable in the clinical setting.

Collectively, the studies investigating PDE inhibition suggest that amplification of the typically NO-dependent cGMP signal benefits both skeletal and cardiac function and mitigates various characteristics of the dystrophic condition in the *mdx* mouse, and in an acute setting, is beneficial in both DMD and BMD patients. Recently, however, a Phase 3 clinical trial of Sildenafil in DMD and BMD boys was prematurely stopped following the absence of improvements in skeletal muscle function and adverse changes to left ventricle volumes (NCT01168908; \[[@CR72]\]). In a parallel Sildenafil trial in only BMD patients, the clinical trial was completed but no obvious benefit to patients was observed (NCT01350154; \[[@CR73]\]). Most recently, a Phase 3 clinical trial in only DMD patients investigating the capacity of Tadalafil to slow the decline of ambulation was prematurely terminated due to lack of efficacy. These clinical data indicate that Tadalafil and Sildenafil are not translatable drugs from pre-clinical studies to patients with DMD when the patients receive treatment for a chronic period of time (i.e., 6 months) or are on standard of care (SoC) therapy. While the inhibition of PDE5A is pre-clinically viable (i.e., in mouse, zebrafish and dog models), it must be kept in mind that these preclinical studies were not performed in conjunction with SoC therapies (i.e., prednisone or deflazacort). From a pharmacological standpoint, both Tadalafil and Sildenafil are drugs marketed for a specific indication (Tadalafil for erectile dysfunction and benign prostatic hyperplasia, Sildenafil for erectile dysfunction and pulmonary arterial hypertension) that happened to find efficacy in other indications both pre-clinically and clinically. The hope of testing drugs like Tadalafil and Sildenafil are that they are already FDA approved, albeit for other indications, and have known safety margins. However, the recent discovery that BMD patients, who express a truncated version of dystrophin, are also deficient in PDE5A \[[@CR73]\] suggests limitations to this therapeutic avenue. This deficiency highlights that as per nNOS, the expression of PDE is intimately linked with dystrophin and/or DPC expression, and that the capacity to exploit them pharmacotherapeutically is therefore limited in DMD. As such, no improvements in cardiac function, blood flow to the skeletal muscle during exercise, or quality of life were observed in BMD patients \[[@CR73]\].

NO donors {#Sec5}
---------

Since ʟ-arginine and PDE activation are both dependent upon the presence of key enzymes/proteins associated with the sarcolemma, and more specifically, the DPC, promoting NO production through the use of NO donors may be of greater benefit to bypass this defective/inefficient protein system. As there is limited nNOS present in dystrophin-deficient skeletal muscle, this significantly impairs the muscles capacity for NO production. Therefore, even with PDE inhibition, the availability of NO would still be significantly diminished. Thus, the use of NO donors is an attractive therapeutic treatment option as they have the capacity to markedly increase systemic NO availability beyond the capacity to endogenously produce it within dystrophic muscle (Fig. [1](#Fig1){ref-type="fig"}).

Indeed, 6 months delivery of a nitric ester derivative of sedative alkyl alcohol (administered at 40 mg/kg 5 days/week) has been shown to enhance the vascular density of skeletal muscle, as well as exercise performance and strength in *mdx* mice, with a marked decrease in the free intracellular Ca^2+^ concentration of skeletal muscle \[[@CR74]\]. In addition, the NO-donating nitric ester increased muscle fibre size while concomitantly reducing the population of regenerating fibres, suggestive of decreased damage \[[@CR74]\]. Similarly, 7 months of 30 mg/kg naproxcinod, a non-steroidal anti-inflammatory drug (NSAID) with NO-donating properties, in food, had a beneficial effect on the running capacity of *mdx* mice with both time to exhaustion and whole body strength improved \[[@CR75]\]. These functional benefits were partnered with improved muscle architecture, and reductions in inflammatory, fibrotic and collagen infiltrate observed in both skeletal and cardiac muscle \[[@CR75]\]. Longer term administration of naproxcinod (at 21 mg/kg/day in food for 9 months) induces similar improvements in the strength and histological properties of cardiac muscle leading to the functional normalisation of ejection fraction time, and systolic blood pressure \[[@CR76]\]. Considering the anti-inflammatory effects of the aforementioned NO-donors, combining a NO donor with NSAIDs could enhance the beneficial effects of NO. Three months of a HCT 1026-enriched diet (NO donor derived from flurbiprofen; 45 mg/kg/day) significantly improved blood flow and alleviated functional ischaemia in *mdx* mice \[[@CR77]\]. A longer term supplementation regimen of the same drug (30 mg/kg/day in food for 12 months) was shown to reduce muscular damage, with concomitant decreases in serum creatine kinase levels and improved mobility of *mdx* mice \[[@CR78]\]. Moreover, the addition of isosorbide dinitrate (30 mg/kg/day) with ibuprofen (50 mg/kg/day) has been shown to induce significant protection of the dystrophic heart by normalising left ventricle mass and wall thickness, maintaining cardiomyocyte number and reducing cross sectional area. Reduced fibrotic tissue content and inflammatory cell infiltration and a concomitant improvement in overall cardiac function was also observed in the *mdx* mouse \[[@CR79]\]. Isosorbide dinitrate, alone (66 mg/kg) or in combination with prednisone (1 mg/kg) for 18 days, also demonstrably improves sarcolemmal integrity, decreases the presence of calcified fibres and stimulates regeneration in the *mdx* diaphragm, however without the addition of ibuprofen, it promoted an increase in heart weight \[[@CR80]\] which was not observed previously \[[@CR79]\]. An increase in cardiac mass, without improvements in cardiac function, is considered an adverse effect of treatment which would promote the normal, progressive cardiac hypertrophy observed in DMD patients. Ibuprofen seems to abate this adverse effect since a safety study in DMD patients using 12 months of isosorbide dinitrate (40 mg/day) and ibuprofen (400 mg/day) maintained cardiac function and reduced systemic inflammatory markers \[[@CR81]\]. Given there is the capacity for non-specific, systemic NO-donors to adversely affect cardiac tissue, the use of skeletal muscle targeted NO donation would be beneficial. Indeed, oral administration of MyoNovin (80 mg/kg) -- a NO donor that specifically donates NO to skeletal muscle -- for 18 days induces similar effects to isosorbide dinitrate in *mdx* mice without the adversity of cardiac hypertrophy induction \[[@CR80]\]. As the majority of the investigated NO donor therapies have additional indications (i.e., as anti-inflammatories (ibuprofen) or muscle relaxants (MyoNovin)), it is difficult to separate out the benefits specifically provided by donated NO and it is possible that that these alternative indications may be the more pertinent effectors. Given that uncontrolled and excessive NO delivery can induce pathological effects including inflammation, mitochondrial dysfunction and myocardial damage \[[@CR82]\], these data suggest that manipulation of the NO-donation delivery system may be pivotal to mitigating the unwanted side effects of NO donor therapy. As delivery of NO to the skeletal muscle is difficult to control with pharmacological NO donors, and needs to be highly regulated since changes in NO concentration can be either beneficial, deleterious or insignificant to the promotion of Ca^2+^dysregulation \[[@CR83]\], availability of a constant yet buffered reserve of NO is important.

Nitrate supplementation {#Sec6}
-----------------------

Recently, it has emerged that dietary supplementation with nitrate increases endogenous NO production via a nNOS-independent pathway (Fig. [1](#Fig1){ref-type="fig"}). Nitrate is an inorganic anion that is abundant in green leafy vegetables including beetroot, lettuce and spinach \[[@CR84]\] and also in carrot, beetroot and pomegranate juices \[[@CR85]\]. The nitrate anion is inert but once ingested, nitrate is reduced by the commensal bacteria in the enterosalivary pathway \[[@CR86]\] into the bioactive nitrite, which then circulates in the blood. Although bioactive, nitrite is further converted to NO via several enzymatic pathways in the blood and tissues, including xanthine oxidase, myoglobin and haemoglobin \[[@CR87]\], to exert a range of physiological effects. Thus, this pathway is complementary to nNOS-derived NO production. Additionally, there is benefit to this nitrate-nitrite-NO pathway as it is reversible. NO can be oxidised back to nitrate by myoglobin and haemoglobin and therefore the capacity to cycle back to nitrate allows for a constant reservoir of NO \[[@CR88]\]. Moreover, since chronic increases in NO bioavailability can be toxic and induce systemic pathology \[[@CR82]\], having an inactive reservoir of buffered NO would be beneficial. Therefore, enhancing the nitrate-nitrite-NO pathway represents a potential pathway that could be exploited to significantly enhance NO availability in dystrophic muscle in a controlled and buffered manner.

Recent studies suggest that nitrate supplementation enhances health and skeletal muscle performance. A 3 day oral supplementation of sodium nitrate (0.1 mmol/kg/day) in healthy males revealed that nitrate significantly improved skeletal muscle mitochondrial bioenergetics by increasing mitochondrial efficiency and decreasing proton leak; and reduced whole body oxygen consumption following submaximal exercise \[[@CR89]\]. Moreover, a 7 day supplementation regimen in drinking water of healthy mice (\~3.75 μmol/day) significantly improved skeletal muscle contractility, particularly of the EDL, by increasing expression of Ca^2+^ handling proteins \[[@CR90]\]. Similar improvements in contractile function have also been observed in humans following acute supplementation with nitrate-rich beetroot juice (0.6 g/300 ml), with the authors noting improved excitation-contraction coupling (at low frequencies) and increased explosive force production in quadriceps \[[@CR91]\]. Acute beetroot supplementation also demonstrably reduces whole body oxygen consumption \[[@CR92]--[@CR95]\], promotes fatigue resistance \[[@CR96]--[@CR99]\] and improves performance times \[[@CR97], [@CR100], [@CR101]\]. Similar data has been observed in rats using dietary sodium nitrate supplementation in drinking water (0.7 mM), which stimulated mitochondrial biogenesis (peroxisome proliferator-activated receptor β/δ and PGC-1α expression) and enhanced bioenergetics in both skeletal \[[@CR102]\] and cardiac muscle \[[@CR103]\] indicating that acute exposure to nitrate supplementation has a modulatory effects on bioenergetics.

The benefits of nitrate supplementation also extend to disease states. In chronic obstructive pulmonary disease patients, acute beetroot juice supplementation improved exercise capacity and decreased blood pressure \[[@CR104], [@CR105]\]. Similar findings -- in addition to increased tissue oxygenation -- were observed in peripheral artery disease patients \[[@CR106]\]. Considering that dystrophic muscle is in a comparable metabolically-stressed state to exercising muscle in that there is an increased metabolic demand and sarcoplasmic \[Ca^2+^\]~,~ and that nitrate supplementation can elicit positive physiological responses in diseased tissue, investigating such a therapy for DMD is rational.

To date, we are the only group to have investigated nitrate supplementation in the *mdx* mouse and its downstream effects on muscle metabolism and architecture \[[@CR107]\]. Previously, it was demonstrated that 8 weeks of 85 mg/L sodium nitrate in drinking water ameliorated metabolic syndrome in endothelial NOS-deficient mice by increased circulating plasma NO levels \[[@CR108]\], suggesting that similar improvements could be observed in the *mdx* mouse through the restoration of NO availability. As metabolic dysfunction and insufficiency is a dominant feature of dystrophin-deficient muscle, we investigated two metabolic pathways that can be mediated by NO --- glucose uptake and mitochondrial function. We demonstrated normal basal- and contraction-induced glucose uptake in *mdx* muscles, which is consistent with previous reports of normal insulin-dependent glucose uptake (which is NO-independent) in dystrophin-deficient muscle \[[@CR109]\]. However, nitrate supplementation was unable to improve the depressed mitochondrial respiration observed in the white and red portions of the gastrocnemius in this study and as reported by us \[[@CR7]\] and others previously (\[[@CR8], [@CR110], [@CR111]\]. In fact, nitrate reduced the maximal respiration in the red gastrocnemius and failed to increase markers of mitochondrial biogenesis such as mitochondrial electron transport chain complex proteins. Our data is consistent with the recent observation that nuclear-specific NO production via localised nNOS is important to modulate nuclear-regulated mitochondrial biogenesis in skeletal muscle \[[@CR112]\]. Thus, non-specific and unregulated NO generation by non-nNOS sources appears to be futile in the absence of nNOS expression and its regulatory function.

One benefit of nitrate supplementation in *mdx* mice that we did observe was reduced hydrogen peroxide generation, indicating reduced oxidative stress at the mitochondrial level \[[@CR107]\]. Outright, the reduction in hydrogen peroxide appeared to be a positive effect; however, it occurred concomitant with a significant increase in reactive nitrogen species generation as determined by the immunolabelling of nitrotyrosine, an indirect marker of peroxynitrite. Peroxynitrite formation corresponded with increased damage of the tibialis anterior muscle as assessed by haematoxylin and eosin staining \[[@CR113]\]. Our finding is in stark contrast to those who have previously demonstrated decreased muscle damage through NO donor therapy \[[@CR78], [@CR114]\], highlighting that the anti-inflammatory compounds often administered in combination with the NO donor in these studies, may be efficaciously offsetting the inflammatory response that can be induced by both NO and NO-induced peroxynitrite-mediated damage.

One clinical trial has also investigated sodium nitrate therapy in BMD patients. In this study, an acute single oral nitrate dose (140 mL beetroot juice concentrate containing 8.4 mmol inorganic nitrate) was shown to improve functional sympatholysis and post-exercise hyperaemia in ambulatory BMD patients \[[@CR115]\]. While we did not measure these parameters in our study, it is most likely that the beneficial effects elicited by nitrate in BMD patients is reflective of the presence of both dystrophin and nNOS in their skeletal muscle, albeit these proteins are often severely, but not exclusively, reduced in BMD patients compared to healthy individuals \[[@CR115]\]. It appears that there is a defined level of nNOS protein, or localisation of nNOS, that must be expressed in skeletal muscle to ensure that the normal and beneficial modulatory effects of bioavailable NO are exerted within the muscle. Indeed, this is apparent not only in our study but also in that of Nelson et al. \[[@CR115]\] who reported several BMD patients that were non-responsive to nitrate therapy. This effect may be due to a more advanced disease/clinical state in these particular patients in which nNOS protein levels become reduced below threshold levels due to escalating dystropathology (i.e., protease activity).

Conclusions {#Sec7}
===========

NO plays an important role in a variety of biological processes and in dystrophin-deficient muscle where NO production is limited due to the secondary reduction of nNOS, it is likely a significant contributor to disease progression. While improvements in muscle function, architecture and metabolism have been demonstrated using various methods to increase NO bioavailability including restoration of the nNOS protein, ˪-arginine supplementation and PDE inhibition, there are also limitations and/or side effects that need to be addressed. This is particularly true since the beneficial effects observed in pre-clinical animal models of DMD have largely failed to translate to clinical improvements in DMD patients. In the one ʟ-arginine supplementation study that has successfully translated in a clinical human DMD pilot trial, these patients were notably steroid naïve, and thus not receiving SoC treatment. These data highlight important drug/functional interactions that clearly require further elucidation. There are also variations in the outcomes at the muscle fibre level with different models of NO induction. For example, beneficial effects have been observed with NO donors, typically in addition with anti-inflammatories or which have additional alternate functions at the muscle level (i.e., as muscle relaxants as per MyoNovin), but not with nitrate supplementation. Moreover, it appears that chronic manipulation of the nitrate-nitrite-NO pathway may not be a viable therapeutic option for DMD given its tendency to promote damage and further dystropathology. While we are currently the only group to have investigated nitrate supplementation as a therapy for DMD, our findings suggest that long-term/chronic nitrate supplementation is detrimental to dystrophin-deficient muscle and may require a concomitant increase in nNOS protein expression to impart the same benefits it does in healthy muscle. This idea is supported by the beneficial effects seen in BMD patients following acute sodium nitrate supplementation, who express low, yet detectable, levels of both dystrophin and nNOS. However, further investigation is required to fully elucidate this intimate relationship. Targeting NO delivery to skeletal muscle with the concomitant induction of nNOS protein expression, appears to be a logical future direction in the utilisation of NO donation as a therapy for DMD. The translational capacity of this research however must address nNOS therapies in conjunction with SoC (i.e., prednisone, deflazacort), as this research is currently lacking in pre-clinical animal models.

AMPK

:   Adenosine monophosphate-activated protein kinase

BMD

:   Becker muscular dystrophy

Ca^2+^

:   Calcium

cGMP

:   Cyclic guanosine monophosphate

DMD

:   Duchenne muscular dystrophy

DPC

:   Dystrophin-associated protein complex

EBD

:   Evans blue dye

EDL

:   extensor digitorum longus

iNOS

:   Inducible neuronal nitric oxide synthase

nNOS

:   Neuronal nitric oxide synthase

NO

:   Nitric oxide

NSAID

:   Non-steroidal anti-inflammatory drug

ONOO^−^

:   Peroxynitrite

PDE

:   Phosphodiesterase

PFK

:   Phosphofructokinase

sGC

:   Soluble guanylyl cyclase

SoC

:   Standard of care
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